Drug Trial Radar · NCT03194893
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jul 5, 2017
Primary completion
Sep 18, 2025
Study completion Sep 18, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
Conditions
- Neoplasms
Interventions
AlectinibDrug
Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
CrizotinibDrug
Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)Time frame: From study initiation until 4 weeks after the last dose (up to approximately 8.19 years)
Locations
29 sites in 9 countries. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Center
Orange, California
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Centre Francois Baclesse
Caen, France
Centre Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Groupe Hospitalier Sud - Hôpital Haut Lévêque
Pessac, France
Hopital Pontchaillou - CHU de Rennes
Rennes, France
CHU de Toulouse - Hôpital Larrey
Toulouse, France
Hopital Robert Schuman
Vantoux, France
Queen Mary Hospital
Hong Kong, Hong Kong
Queen Elizabeth Hospital Department of Clinical Oncology
Kowloon, Hong Kong
Irccs Centro Di Riferimento Oncologico (CRO)
Aviano, Friuli Venezia Giulia, Italy
Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1
Rome, Lazio, Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, Tuscany, Italy
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
Perugia, Umbria, Italy
Uniwersyteckie Centrum Kliniczne
Gda?sk, Poland
FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
Moscow, Moscow Oblast, Russia
University ?linic of headaches
Moscow, Moscow Oblast, Russia
City Clinical Oncology Hospital
Moscow, Moscow Oblast, Russia
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital del Mar
Barcelona, Spain
Hospital Universitari Dexeus - Grupo Quironsalud
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Adana Ac?badem Hospital Oncology Department
Adana, Turkey (Türkiye)
Istanbul Uni Capa Medical Faculty
Istanbul, Turkey (Türkiye)
Ege University Medical Faculty
Izmir, Turkey (Türkiye)
Hacettepe Uni Medical Faculty Hospital
S?hhiye, Ankara, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.